Tesofensine NS-2330|cas:195875-84-4|西域试剂

Tesofensine NS-2330,99.35%

产品编号：Bellancom-14472| CAS NO：195875-84-4| 分子式：C₁₇H₂₃Cl₂NO| 分子量：328.28

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-14472	￥2400.00	杭州北京（现货）
Bellancom-14472	￥3800.00	杭州北京（现货）
Bellancom-14472	￥7200.00	杭州北京（现货）
Bellancom-14472	￥11500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Tesofensine NS-2330

产品介绍

Tesofensine (NS-2330) 是一种三元单胺再摄取抑制剂，可有效抑制神经递质多巴胺 (DA; IC₅₀=6.5 nM)、去甲肾上腺素 (NE;IC₅₀=1.7 nM) 和血清素 (5-HT;IC₅₀=11 nM) 在突触间隙中的再摄取，并具有作为抗肥胖剂的潜力。Tesofensine 是一种中枢神经系统作用的抗肥胖剂。

生物活性

Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC₅₀=6.5 nM), norepinephrine (NE;IC₅₀=1.7 nM), and serotonin (5-HT;IC₅₀=11 nM), and with potentials as an anti-obesity agent. Tesofensine is a CNS acting anti-obesity agent.

体外研究

体内研究

Tesofensine (a single dose of 0.1-3 mg/kg, s.c.) induces hypophagia in the DIO rat. A single dose of Tesofensine (0. 1-3 mg/kg, s.c.) robustly and dose dependently inhibits food intake in DIO rats over the 12 h nocturnal observation period. Daily administration of a moderate dose of Tesofensine (2.0 mg/kg, s.c.) over 16 days triggers a significant reduction in body weight after 4 days of administration relative to vehicle-treated controls.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Diet-induced obesity (DIO) rat
Dosage:	0.1-3 mg/kg
Administration:	Administered subcutaneously (s.c.); a single dose (acute treatment)
Result:	The threshold dose for inhibition of total food intake was 1.0 mg/kg. The ED₅₀ for inhibition of total food intake in DIO rats was estimated to be 1.3 mg/kg.

Animal Model:	Diet-induced obesity (DIO) rat
Dosage:	2.0 mg/kg
Administration:	Administered subcutaneously (s.c.) daily for over 16 days (chronic treatment)
Result:	The average relative decrease in the body weight of tesofensine-treated DIO rats over the entire treatment period was 8.6±1.4%. When comparing to vehicle controls, the relative weight loss with tesofensine was 13.8±1.4%.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Diet-induced obesity (DIO) rat
Dosage:	0.1-3 mg/kg
Administration:	Administered subcutaneously (s.c.); a single dose (acute treatment)
Result:	The threshold dose for inhibition of total food intake was 1.0 mg/kg. The ED₅₀ for inhibition of total food intake in DIO rats was estimated to be 1.3 mg/kg.

Animal Model:	Diet-induced obesity (DIO) rat
Dosage:	2.0 mg/kg
Administration:	Administered subcutaneously (s.c.) daily for over 16 days (chronic treatment)
Result:	The average relative decrease in the body weight of tesofensine-treated DIO rats over the entire treatment period was 8.6±1.4%. When comparing to vehicle controls, the relative weight loss with tesofensine was 13.8±1.4%.

性状

Solid

溶解性数据

In Vitro:

DMSO : 2 mg/mL (6.09 mM; Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.0462 mL	15.2309 mL	30.4618 mL
5 mM	0.6092 mL	3.0462 mL	6.0924 mL
10 mM	---	---	---

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo: